UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell ...

Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial ...

Sun Pharma has agreed a takeover deal with US biotech Checkpoint Therapeutics, which recently claimed FDA approval for its first drug but is also running low on cash. The Indian pharma group ...

On Sunday, India-based Sun Pharmaceutical Industries Limited agreed to acquire U.S.-based immunotherapy and targeted oncology company Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) for an upfront ...

Healthcare & Pharmaceuticalscategory· March 10, 2025 India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million India's Sun Pharmaceutical Industries said on Monday it will acquire ...

Sun Pharma is pleased to announce that it will acquire Checkpoint Therapeutics Inc, a commercial-stage targeted oncology company. The acquisition strengthens our global specialty offering in our ...

What's Sun Pharmaceutical Industries Ltd share price today. Get Sun Pharmaceutical Industries Ltd latest news on BSE/NSE stock price live updates, Sun Pharmaceutical Industries Ltd financial results ...

Sun Pharmaceutical Industries Ltd. closed 11.47% below its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.

Sun Pharmaceutical Industries Ltd. closed 10.33% short of its 52-week high of 1,960.20 rupees, which the company reached on ...

Sun Pharmaceutical Industries or Sun Pharma is India’s leading pharmaceutical firm which is known for the production of Active Pharmaceutical Ingredients (APIs). The company is headquartered in ...

ALSO READ: Sensex, Nifty Surge Over 4% in 1 Week: What should investors, traders do? The Nifty 500 and BSE 500 are stock exchanges NSE and BSE's broadest indices, respectively. Top Gainers & Losers: ...

Discover Lantern Pharma's transformative 2024 journey in precision oncology with AI breakthroughs, global trial expansions, and key clinical milestones ...